Is ImageneBio, Inc. (IMA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.3% / 30% | 18.6% / 30% | 0.1% / 30% | 10.69% / 5% | ✗ NOT HALAL |
| DJIM | 12.3% / 33% | 18.6% / 33% | 0.1% / 33% | 10.69% / 5% | ✗ NOT HALAL |
| MSCI | 50.5% / 33% | 76.1% / 33% | 0.5% / 33% | 10.69% / 5% | ✗ NOT HALAL |
| S&P | 12.3% / 33% | 18.6% / 33% | 0.1% / 33% | 10.69% / 5% | ✗ NOT HALAL |
| FTSE | 50.5% / 33% | 76.1% / 33% | 0.5% / 50% | 10.69% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -6056.4% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -68.9% | |
| Return on Assets (ROA) | -35.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$48M |
| Free Cash Flow | -$48M |
| Total Debt | $3M |
| Debt-to-Equity | 2.2 |
| Current Ratio | 12.5 |
| Total Assets | $153M |
Price & Trading
| Last Close | $5.40 |
| 50-Day MA | $6.50 |
| 200-Day MA | $9.61 |
| Avg Volume | 43K |
|
52-Week Range
$3.94
| |
About ImageneBio, Inc. (IMA)
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ImageneBio, Inc. (IMA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ImageneBio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ImageneBio, Inc.'s debt ratio?
ImageneBio, Inc.'s debt ratio is 12.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 50.5%.
What are ImageneBio, Inc.'s key financial metrics?
ImageneBio, Inc. has a market capitalization of $56M, and revenue of $800,000. Return on equity stands at -68.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.